Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.

Abstract: Provided herein are pharmaceutical compositions, intravitreal implants and particle suspensions comprising a polymer matrix and at lest one therapeutic agent that is released in a substantially linear manner for a particular duration.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: A sub-pixel rendering data conversion apparatus including an inverse sub-pixel rendering circuit and a sub-pixel rendering circuit is provided. The inverse sub-pixel rendering circuit receives the first sub-pixel rendering data converted from the first true image data and converting the first sub-pixel rendering data to the second true image data, and the first sub-pixel rendering data includes data of the first sub-pixel rendering arrangement. The sub-pixel rendering circuit converts the second true image data to the second sub-pixel rendering data and outputs the second sub-pixel rendering data to a display panel, the second sub-pixel rendering data includes data of the second sub-pixel rendering arrangement, and the display panel includes a plurality of sub-pixels arranged in the manner of the second sub-pixel rendering arrangement.

Abstract: A sub-pixel rendering data conversion apparatus including an inverse sub-pixel rendering circuit and a sub-pixel rendering circuit is provided. The inverse sub-pixel rendering circuit receives the first sub-pixel rendering data converted from the first true image data and converting the first sub-pixel rendering data to the second true image data, and the first sub-pixel rendering data includes data of the first sub-pixel rendering arrangement. The sub-pixel rendering circuit converts the second true image data to the second sub-pixel rendering data and outputs the second sub-pixel rendering data to a display panel, the second sub-pixel rendering data includes data of the second sub-pixel rendering arrangement, and the display panel includes a plurality of sub-pixels arranged in the manner of the second sub-pixel rendering arrangement.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Provided herein are mono-(acid) salts of a compound of a Formulae provided herein. Also provided herein are compositions comprising a mono-(acid) salt of a compound of a Formulae provided herein. Also provided herein are pharmaceutical compositions comprising a mono-(acid) salt of a compound of a Formulae provided herein. Also provided herein are methods of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a mono-(acid) salt of a compound of a Formulae provided herein.

Abstract: A brightness compensation method and a brightness compensation circuit for a display device are provided. The brightness compensation method includes the following steps. Receive original image data. Receive backlight timing parameters. Perform brightness compensation according to the image data and the backlight timing parameters. The step of performing brightness compensation includes adjusting at least one of pixel driving data, a driving gamma level, and a driver boost level.

Abstract: A brightness compensation method and a brightness compensation circuit for a display device are provided. The brightness compensation method includes the following steps. Receive original image data. Receive backlight timing parameters. Perform brightness compensation according to the image data and the backlight timing parameters. The step of performing brightness compensation includes adjusting at least one of pixel driving data, a driving gamma level, and a driver boost level.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.